Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

NCT06462183 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Adenoid Cystic Carcinoma
Colorectal Cancer

Interventions

DRUG: RGT-61159

Sponsor

Rgenta Therapeutics Inc